NG Biotech and Hardy Diagnostics Secure FDA Breakthrough Status for AMR Assays

The recent announcement that NG Biotech and Hardy Diagnostics have secured FDA Breakthrough Device Designation for their NG-TEST Candida auris and NG-TEST Aci assays marks a significant pivot in the clinical management of antimicrobial resistance (AMR). By granting this status, the FDA acknowledges that these rapid diagnostic tools address an unmet medical need for life-threatening or irreversibly debilitating conditions. The designation is specifically designed to accelerate the development, assessment, and review of medical devices that provide more effective treatment or diagnosis of such diseases, providing the companies with intensive interactive feedback from the FDA and a prioritized review process.

The clinical significance of these two specific targets cannot be overstated. Candida auris is a multi-drug resistant fungal pathogen that has become a global health threat due to its ability to cause invasive infections with high mortality rates and its propensity for persistent outbreaks in healthcare settings. Traditional identification methods for C. auris can take several days, as they often rely on culture-based techniques that may misidentify the fungus. Similarly, Acinetobacter baumannii (the target of the NG-TEST Aci) is a Gram-negative bacterium frequently associated with hospital-acquired pneumonia and bloodstream infections, often exhibiting resistance to nearly all available antibiotics, including carbapenems. The ability to identify these pathogens in minutes rather than days allows for immediate patient isolation and the implementation of targeted antimicrobial therapy, which is critical for both individual patient outcomes and broader hospital stewardship.

“

From a market perspective, the partnership between the French-based NG Biotech and the California-based Hardy Diagnostics represents a strategic move to penetrate the lucrative and highly regulated U.S.

From a market perspective, the partnership between the French-based NG Biotech and the California-based Hardy Diagnostics represents a strategic move to penetrate the lucrative and highly regulated U.S. diagnostic market. Hardy Diagnostics, a well-established player in the microbiology sector, provides the distribution infrastructure and regulatory expertise necessary to scale NG Biotech’s lateral flow technology across American healthcare systems. This collaboration positions both companies to compete more effectively against larger diagnostic conglomerates like BioMérieux and Danaher’s Cepheid, which have dominated the rapid molecular testing space. By focusing on rapid phenotypic or protein-based detection rather than complex molecular sequencing, NG Biotech offers a potentially more cost-effective and user-friendly solution for point-of-care or near-patient testing.